Telix Pharmaceuticals Ltd. ( (AU:TLX) ) just unveiled an update.
Telix Pharmaceuticals Ltd. has announced a change in the indirect interest of its director, Dr. Christian Behrenbruch, who disposed of 2,000,000 fully paid ordinary shares held by Elk River Holdings Pty Ltd as Trustee for The Behrenbruch Family Trust. This transaction, valued at $29.50 per share, reduces the indirect interest to 20,675,000 shares, potentially impacting the company’s market perception and stakeholder confidence.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Ltd. operates in the biotechnology industry, focusing on the development and commercialization of diagnostic and therapeutic products using molecularly targeted radiation. The company is primarily engaged in creating innovative solutions for cancer treatment, leveraging its expertise in radiopharmaceuticals to address unmet medical needs.
YTD Price Performance: 39.99%
Average Trading Volume: 4,810
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $6.65B
Learn more about TLX stock on TipRanks’ Stock Analysis page.